We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia Healthcare Company Inc. (ACHC - Free Report) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents. Earnings were flat year over year.
Quarter Details
The company registered 42% year-over-year growth in revenues in the quarter. However, the quarterly revenues of approximately $702 million missed the consensus mark by $5 million, failing to impress investors.
The year-over-year upside in revenues may be attributed to the addition of beds at Acadia’s facilities and 6.3% increase in same facility revenues. The improvement in same facility revenues, in turn, can be attributed to a 6.1% rise in patient days. Notably, revenue per patient day inched up 0.1% on a year-over-year basis.
The U.S. same facility revenues were up 6.6% from the year-ago quarter. The company also recorded a 6.5% increase in patient days from 2015.
The U.K. same facility revenues inched up 4.2% year over year to $73 million. Number of patient days rose 4.7% from the year-ago quarter.
We note that revenues per patient day were up 0.1% in the U.S. but down 1.0% in the U.K.
Total expenses increased 49% year over year to $660.5 million.
Same facility adjusted EBITDA margin was 26.3% compared with 26.0% in the year-ago quarter.
2016 Highlights
Adjusted earnings came at $2.45 per share on revenues of $2.8 billion. While revenues grew 56%, the bottom line improved 10%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Cash and cash equivalents at year-end 2016 were $57.1 million, up from $11.2 million at year-end 2015.
Long term debt increased to $3.2 billion from $2.2 billion at the end of 2015.
Net cash provided by operating activities of $361.5 million increased 49% from 2015.
2017 Guidance
Acadia Healthcare estimates adjusted earnings per diluted between $2.40 and $2.50 on revenues between $2.85 billion and $2.9 billion.
Adjusted EBITDA is expected between $625 million and $640 million.
For first quarter, adjusted earnings per diluted share is projected in the range of 45–47 cents.
Zacks Rank and Performance of Other Stocks
Acadia Healthcare carries Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other medical stocks, Abbott Laboratories (ABT - Free Report) , Advanced Accelerator Applications S.A. and AmerisourceBergen Corporation (Holding Co) have surpassed their respective Zacks Consensus Estimate in the last reported quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View
Acadia Healthcare Company Inc. (ACHC - Free Report) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents. Earnings were flat year over year.
Quarter Details
The company registered 42% year-over-year growth in revenues in the quarter. However, the quarterly revenues of approximately $702 million missed the consensus mark by $5 million, failing to impress investors.
The year-over-year upside in revenues may be attributed to the addition of beds at Acadia’s facilities and 6.3% increase in same facility revenues. The improvement in same facility revenues, in turn, can be attributed to a 6.1% rise in patient days. Notably, revenue per patient day inched up 0.1% on a year-over-year basis.
The U.S. same facility revenues were up 6.6% from the year-ago quarter. The company also recorded a 6.5% increase in patient days from 2015.
The U.K. same facility revenues inched up 4.2% year over year to $73 million. Number of patient days rose 4.7% from the year-ago quarter.
We note that revenues per patient day were up 0.1% in the U.S. but down 1.0% in the U.K.
Total expenses increased 49% year over year to $660.5 million.
Same facility adjusted EBITDA margin was 26.3% compared with 26.0% in the year-ago quarter.
2016 Highlights
Adjusted earnings came at $2.45 per share on revenues of $2.8 billion. While revenues grew 56%, the bottom line improved 10%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise | Acadia Healthcare Company, Inc. Quote
Financial Update
Cash and cash equivalents at year-end 2016 were $57.1 million, up from $11.2 million at year-end 2015.
Long term debt increased to $3.2 billion from $2.2 billion at the end of 2015.
Net cash provided by operating activities of $361.5 million increased 49% from 2015.
2017 Guidance
Acadia Healthcare estimates adjusted earnings per diluted between $2.40 and $2.50 on revenues between $2.85 billion and $2.9 billion.
Adjusted EBITDA is expected between $625 million and $640 million.
For first quarter, adjusted earnings per diluted share is projected in the range of 45–47 cents.
Zacks Rank and Performance of Other Stocks
Acadia Healthcare carries Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other medical stocks, Abbott Laboratories (ABT - Free Report) , Advanced Accelerator Applications S.A. and AmerisourceBergen Corporation (Holding Co) have surpassed their respective Zacks Consensus Estimate in the last reported quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>